Amador Bioscience, a US-based global translational sciences and clinical pharmacology CRO, announced on Friday that it has named Dr Meina Liang as its new chief technology officer.
In the new role, the company said that Dr Liang is to head the strategy to establish cutting-edge bioanalysis technologies and capabilities, improving the company's global-standard services to biopharmaceutical companies.
Dr Liang has served as executive director and global head of Integrated Bioanalysis at AstraZeneca. She has held various scientist and leadership positions with increasing responsibilities at Berlex Bioscience/Schering AG, Abgenix/Amgen, and Medimmune.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer